Safety Analysis of Intravenous Rapid Infusion of Obinutuzumab in Patients With B-cell Non-Hodgkin's Lymphoma in China
Clinical trial NCT05510219 · UNKNOWN
Trial details
- NCT number
- NCT05510219
- Sponsor
- The First Affiliated Hospital with Nanjing Medical University
- Status
- UNKNOWN
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2022-01-01
- Primary completion
- 2023-12-31
- Enrollment
- 200
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.